Literature DB >> 16466657

Clinical and pathological prognostic factors in squamous cell carcinoma of the vulva.

Francesco Raspagliesi1, Francesco Hanozet, Antonino Ditto, Eugenio Solima, Flavia Zanaboni, Francesca Vecchione, Shigeki Kusamura.   

Abstract

OBJECTIVE: The objective of this study was the prognostic analysis of clinicopathologic variables related to primary tumor and to lymph node metastases.
METHODS: We retrospectively analyzed 389 cases of squamous cell carcinoma of the vulva. The following variables were studied: patients' age, diameter and location of the tumor, clinical tumor characteristics, depth of invasion, grade, lymphovascular space involvement (LVSI) and lymph node status. In the subset of 110 node positive patients, we evaluated number of positive nodes, laterality, extension of node dissection, lymph node chains involved, presence of extracapsular spread and rate of lymph node replacement. All variables with P value < 0.2 by the univariate analysis were successively subjected to multivariate analysis (Cox proportional hazard model).
RESULTS: Among all the tumor-related variables age, clinical tumor characteristics, LVSI and lymph node status were found to be statistically significant predictors of survival for the log-rank test. On the basis of multivariate analysis, the nodal status was the most significant independent prognostic factor (hazard rate [HR]: 2.06; confidence interval [CI] 95%: 1.57-12.07) followed by LVSI (HR: 3.47; CI95%: 1.85-7.85). The independent prognostic factors among the variables relative to positive nodes were the percentage of nodal replacement (HR: 6.99; CI95%: 3.51-16.14) and the extracapsular spread (HR: 4.88; CI95%: 2.96-10.14).
CONCLUSIONS: Lymph node status and nodal features, such as extracapsular spread and nodal replacement rate, were shown to be independent factors. These factors should be considered to identify high risk patients and in planning further adjuvant therapy.

Entities:  

Mesh:

Year:  2006        PMID: 16466657     DOI: 10.1016/j.ygyno.2005.12.027

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  16 in total

1.  Diagnosis, Therapy and Follow-up Care of Vulvar Cancer and its Precursors. Guideline of the DGGG and DKG (S2k-Level, AWMF Registry Number 015/059, November 2015.

Authors:  H G Schnürch; S Ackermann; C D Alt; J Barinoff; C Böing; C Dannecker; F Gieseking; A Günthert; P Hantschmann; L C Horn; R Kürzl; P Mallmann; S Marnitz; G Mehlhorn; C C Hack; M C Koch; U Torsten; W Weikel; L Wölber; M Hampl
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-10       Impact factor: 2.915

2.  Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.

Authors:  Koji Matsuo; Todd B Sheridan; Seiji Mabuchi; Kiyoshi Yoshino; Kosei Hasegawa; Kimberley D Studeman; Dwight D Im; Neil B Rosenshein; Lynda D Roman; Anil K Sood
Journal:  Gynecol Oncol       Date:  2014-03-25       Impact factor: 5.482

3.  Risk factors and temporal patterns of recurrences in patients with vulvar cancer: implications for follow-up intervals and duration.

Authors:  Katharina Röhrmoser; Atanas Ignatov; Michael Gerken; Olaf Ortmann; Monika Klinkhammer-Schalke; Thomas Papathemelis
Journal:  J Cancer Res Clin Oncol       Date:  2022-02-18       Impact factor: 4.553

4.  Observational multicenter Italian study on vulvar cancer adjuvant radiotherapy (OLDLADY 1.2): a cooperation among AIRO Gyn, MITO and MaNGO groups.

Authors:  Gabriella Macchia; Calogero Casà; Martina Ferioli; Valentina Lancellotta; Donato Pezzulla; Brigida Pappalardi; Concetta Laliscia; Edy Ippolito; Jacopo Di Muzio; Alessandra Huscher; Francesca Tortoreto; Mariangela Boccardi; Roberta Lazzari; Pierandrea De Iaco; Francesco Raspagliesi; Angiolo Gadducci; Giorgia Garganese; Gabriella Ferrandina; Alessio Giuseppe Morganti; Luca Tagliaferri
Journal:  Radiol Med       Date:  2022-09-10       Impact factor: 6.313

5.  [Pathoanatomical preparation and reporting of specimens from precancerous lesions and carcinomas of the vulva].

Authors:  L-C Horn; K Schierle; K Klostermann; H-G Schnürch; P Hantschmann
Journal:  Pathologe       Date:  2009-02       Impact factor: 1.011

6.  Estimation of groin recurrence risk in patients with squamous cell vulvar carcinoma by the assessment of marker gene expression in the lymph nodes.

Authors:  Magdalena Kowalewska; Jakub Radziszewski; Krzysztof Goryca; Mateusz Bujko; Malgorzata Oczko-Wojciechowska; Michal Jarzab; Janusz Aleksander Siedlecki; Mariusz Bidzinski
Journal:  BMC Cancer       Date:  2012-06-06       Impact factor: 4.430

7.  Hemoglobin level predicts outcome for vulvar cancer patients independent of GLUT-1 and CA-IX expression in tumor tissue.

Authors:  Hedwig P van de Nieuwenhof; Joanne A de Hullu; Johannes H A M Kaanders; Johan Bulten; Leon F A G Massuger; Léon C L T van Kempen
Journal:  Virchows Arch       Date:  2010-10-02       Impact factor: 4.064

8.  Role of paclitaxel and cisplatin as the neoadjuvant treatment for locally advanced squamous cell carcinoma of the vulva.

Authors:  Francesco Raspagliesi; Flavia Zanaboni; Fabio Martinelli; Santiago Scasso; Joel Laufer; Antonino Ditto
Journal:  J Gynecol Oncol       Date:  2014-01-08       Impact factor: 4.401

9.  Significance of lymphovascular space invasion in epithelial ovarian cancer.

Authors:  Koji Matsuo; Todd B Sheridan; Kiyoshi Yoshino; Takahito Miyake; Karina E Hew; Dwight D Im; Neil B Rosenshein; Seiji Mabuchi; Takayuki Enomoto; Tadashi Kimura; Anil K Sood; Lynda D Roman
Journal:  Cancer Med       Date:  2012-09-14       Impact factor: 4.452

Review 10.  Feasibility and Safety of Video Endoscopic Inguinal Lymphadenectomy in Vulvar Cancer: A Systematic Review.

Authors:  Chai-E Liu; Yan Lu; De-Sheng Yao
Journal:  PLoS One       Date:  2015-10-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.